On a 19-station rotary tablet press operating at 40–60 rpm with 8.0 mm concave punches, a spray-dried Coicis Semen extract derived from Coix lacryma-jobi L. var. ma-yuen seed and standardised to a polysaccharide content of 20–40% w/w exhibits capping at main compression forces above 18 kN unless the extract loading is held below 15 wt% of core weight. The direct compression platform for companion-animal multi-herb tablets therefore combines the veterinary-grade API with dibasic calcium phosphate dihydrate at 25–40 wt%, microcrystalline cellulose PH-102 at 20–30 wt%, croscarmellose sodium at 2.0–4.0 wt%, and magnesium stearate at 0.5–1.0 wt%; the extract addition ratio of 8–15 wt% is set by the hygroscopicity of the spray-dried material, which has a loss on drying of ≤5.0% and a water activity of 0.25–0.35. Industry compliance for a formulation of this type in export markets is anchored to 21 CFR 210/211 current good manufacturing practice for finished veterinary pharmaceuticals, with in-process controls referencing USP <701> disintegration (≤30 minutes in water at 37°C), USP <905> uniformity of dosage units with acceptance value ≤15.0, and USP <1216> friability at ≤1.0% after 100 revolutions. The downstream production sequence is blending in a 600 L tumble or diffusion mixer for 15–20 minutes, pre-compression at 4–6 kN when a slugging step is required for low-bulk-density extract lots, and final compression to hardness 60–90 N; tablet press dwell time is maintained between 30–50 ms to reduce elastic recovery and edge chipping. Terminal product types are 250 mg and 500 mg core-weight tablets, typically packed in 60-count HDPE bottles with silica gel desiccant and induction-sealed liners, for multi-herb veterinary use where a national or regional monograph permits botanical active substance use.

What Limits Fill Weight Uniformity for Vegetal Capsule Powders?

Hard gelatin capsule filling of a milled Coicis Semen extract is constrained by the powder’s Carr index, which rises from 22–28% at ≤35% RH to 38–45% after unprotected exposure at 60% RH for 4 hours, a behaviour observed on production floors without dehumidified hopper feeders. Formulations therefore use a roller-compacted dry granulate rather than a raw spray-dried powder; the extract addition ratio in the final filled blend is held at 25–35 wt%, with the balance as mannitol or lactose monohydrate, pregelatinised starch at 5–10 wt%, and sodium stearyl fumarate at 0.5–1.5 wt% to reduce punch sticking on the tamping pins. Compliance for the capsule presentation follows 21 CFR 211 for finished veterinary pharmaceuticals, with batch release testing under USP <905> uniformity of dosage units (acceptance value ≤15.0), USP <701> disintegration for hard capsules (≤30 minutes at 37°C), and USP <61>/<62> microbial limits for nonsterile oral products; where export requires mycotoxin control, aflatoxin B1 is tested by AOAC 991.31 with a maximum of 0.02 mg/kg. The downstream process is slugging or roller compaction at 8–14 kN roller force, milling through a 0.8 mm screen, blending for 10–15 minutes, then filling into size 3 or 4 hard gelatin capsules on an automatic capsule machine at 50,000–100,000 capsules/h; environmental controls maintain 20–25°C and ≤40% RH, and finished capsules are de-dusted and passed through a metal detector with ferrous and non-ferrous test pieces of 0.5 mm. Terminal product types are 150 mg and 250 mg net content hard gelatin or vegetarian capsules, packed in aluminium-PVC/PVDC blisters or HDPE containers with tamper-evident seals.

A 2017–2020 field audit of poultry drinking-water lines in Southeast Asia repeatedly recorded residual polysaccharide films at nipple drinker outlets when spray-dried extract was dry-blended above 40 wt% with insufficient carrier; the films were less frequent when the extract-to-carrier ratio was lowered to 20–30 wt% active dry extract in a dextrose monohydrate or lactose carrier, corresponding to an in-use dilution of 0.5–2.0 g/L drinking water. The soluble oral powder presentation for swine and poultry is therefore formulated as a free-flowing admixture with moisture content ≤4.0%, pH of a 1.0 g/L solution between 6.0–7.5, and 80-mesh sieve retention of ≤5.0%; because this presentation is often marketed under feed or drinking-water additive frameworks rather than as a finished pharmaceutical, compliance is split between EU Regulation (EC) No 1831/2003 for feed additives, Regulation (EC) No 767/2009 for feed materials, and Directive 2002/32/EC for undesirable substances such as aflatoxin B1 at ≤0.02 mg/kg, while pharmaceutical-grade exports additionally apply 21 CFR 210/211 if the product is registered as an animal drug. The downstream process is dry blending in a 500 L ribbon mixer with fill level 60–70% for 15–20 minutes, passing through an 80-mesh centrifugal sifter to break agglomerates, and packaging in 100 g, 500 g, and 1 kg aluminium-foil sachets at ≤35% RH; for hard-water use, a citrate buffer preblend at 1.0–2.0 wt% is included to reduce precipitation of calcium-chelated polysaccharide fractions. Terminal product types are water-soluble sachets and pouches for in-line medication or feed-additive use in poultry and swine drinking-water systems, supplied with measuring scoops calibrated to 5 g and 25 g.

In fluid-bed granulation, the addition rate of a water-based binding solution containing 30–45% w/w Coicis Semen dry extract is governed by the liquid saturation point of the spray-dried seed material, which begins to over-wet at spray rates above 120 g/min in a 50 L fluid-bed bowl with inlet air temperature 55–65°C and product temperature held at 35–45°C. The granule presentation for feed top-dressing uses a final extract addition ratio of 30–45 wt% in the dried granule, with maltodextrin at 10–20 wt% and povidone K30 at 2.0–4.0 wt% as binder, and is dried to a loss on drying of 2.0–3.0%; particle size is controlled by a 0.5–1.0 mm sieve fraction after dry milling, with fines below 150 µm limited to ≤20% to reduce dust. Industry compliance for the granule as a nonsterile oral dosage form is tied to USP <701> disintegration where applicable to the granule matrix, USP <786> particle size distribution by analytical sieving, USP <616> bulk and tapped density with bulk density 0.45–0.60 g/cm³, and USP <61>/<62> microbial enumeration; if the granule is shipped for feed top-dressing rather than as a finished premix, EU Regulation (EC) No 767/2009 and Directive 2002/32/EC apply. The downstream production process is high-shear pre-mixing in a 100 L granulator at impeller speed 200–300 rpm for 3–5 minutes, binder addition over 8–12 minutes, wet massing for an additional 2–4 minutes, and fluid-bed drying to end-point; granules are then sized, sampled at 10-minute intervals for loss on drying, and packaged in 100 g and 500 g PET/Al/PE laminate pouches. Terminal product types are dried granules for direct top-dressing onto feed or for reconstitution by the farmer, supplied as single-dose or multi-dose pouches with desiccant sachets.

When a Premix Is Diluted Below 2 kg/tonne Complete Feed, Segregation Boundaries Emerge

The dry premix route uses a mineral or organic carrier such as calcium carbonate at 60–70 wt% or corncob meal at 20–30 wt%, with a Coicis Semen extract addition ratio of 5–10 wt% and a vegetable oil binder at 1.0–2.0 wt% to control dust and segregation. Once the premix is diluted into complete feed at 0.5–2.0 kg/tonne, segregation tests with copper sulfate tracer show relative standard deviation (RSD) values rising from ≤5.0% at 2.0 kg/tonne to 8–12% at 0.5 kg/tonne when a single-shaft paddle mixer is discharged directly into the feed line without an intermediate surge bin; the result is a practical lower boundary for uniform distribution. Compliance for this presentation sits within EU Regulation (EC) No 1831/2003 where an additive claim is made, Regulation (EC) No 767/2009 for feed materials, and Directive 2002/32/EC for aflatoxin B1 at ≤0.02 mg/kg and heavy-metal limits; good manufacturing practice for feed is guided by FAO/WHO Codex Alimentarius CAC/RCP 54-2004, and in the United States the applicable framework is the Food Safety Modernization Act preventive controls for animal food under 21 CFR Part 507. The downstream production process is carrier drying to ≤8.0% moisture, sifting through 0.8 mm, loading a 1,000 L ribbon mixer to 60–70% capacity, dry blending for 10–15 minutes, spraying mineral oil at 1.0–2.0 wt% over 3–5 minutes, and final mixing for 5–8 minutes; batch homogeneity is confirmed by tracer assay at 10 sampling points with acceptance RSD ≤5.0%. Terminal product types are 20 kg multi-wall paper bags with inner polyethylene liners, labelled for inclusion at 0.5–2.0 kg/tonne complete feed, intended for feed mills or on-farm micro-dosing systems.

Injectable Polysaccharide Solutions: Endotoxin, pH Drift, and Sterilising-Grade Filtration Limits

An injectable presentation of Coicis Semen extract must be treated as a high-risk development configuration because published data on the compatibility of its polysaccharide fraction with terminal steam sterilisation are limited; a formulation feasibility screen at 5.0–20.0 mg/mL dry extract equivalent in water for injection shows pH drift from 6.5 to 5.2–5.8 after autoclaving at 121°C for 15 minutes, accompanied by a measurable increase in colour units and a viscosity reduction of 10–15% in dilute solutions. The addition ratio for experimental batches is therefore held at 5.0–20.0 mg/mL, with isotonicity adjusted with sodium chloride at 0.7–0.9% w/v and pH stabilised with citrate or phosphate buffer at 5.5–6.5; terminal sterilisation is preferred where stability data permit, otherwise aseptic filtration with a 0.22 µm PES or PVDF membrane is used. Compliance for any registered injectable veterinary drug must meet 21 CFR 210/211 for finished pharmaceuticals, USP <1> Injections, USP <85> bacterial endotoxins with a limit of ≤0.5 EU/mg or a product-specific limit, USP <788> particulate matter in injections, USP <790> visible particulates, and Ph. Eur. 2.6.14 for pyrogens; container closure integrity is verified by USP <1207> dye-ingress test or equivalent. The downstream production sequence is dissolution of the extract in WFI at 20–25°C under low-shear mixing, pH adjustment, pre-filtration through 0.45 µm followed by 0.22 µm sterilising-grade membrane, filling into 10 mL or 20 mL amber Type I glass vials under Class A laminar flow, and autoclaving or aseptic lyophilisation when the product is presented as a sterile powder for reconstitution. Terminal product types are injectable vials or lyophilised cakes for reconstitution; however, regulatory acceptance in the EU/US cannot be assumed without a specific veterinary marketing authorisation, and the formulation should be regarded as a development-stage option rather than a commercial veterinary medicinal product in markets without an existing monograph. The solution must not be mixed with strongly acidic diluents below pH 4.0 or with oxidising agents because polysaccharide precipitation and browning have been observed in forced-degradation studies.

Hot-Filled Oral Drench Stability and the 85°C Preservative Sorption Boundary

An oral drench solution containing 1.0–2.0% w/v Coicis Semen dry extract is hot-filled at 85°C for 30 seconds into high-density polyethylene bottles, but two process boundaries must be controlled: fill temperatures above 90°C increase sorption of potassium sorbate at 0.1–0.2% w/v and sodium benzoate at 0.1% w/v onto the bottle wall, reducing preservative recovery by 3–8% during accelerated stability at 40°C/75% RH; and pH below 4.0 reduces coixol solubility and produces visible haze. The addition ratio for the oral solution is 1.0–2.0% w/v dry extract, with glycerin at 5.0–15.0% w/v as co-solvent and density modifier, citric acid/sodium citrate buffer to maintain pH 4.5–5.5, and purified water as diluent. Compliance for the oral solution as a nonsterile liquid veterinary preparation follows 21 CFR 210/211, with release tests under USP <51> antimicrobial effectiveness testing, USP <61>/<62> microbial enumeration and specified organisms, USP <785> osmolality where product osmolarity is labelled, and Ph. Eur. 5.1.3 for efficacy of antimicrobial preservation; if the product is exported as an oral feed adjunct rather than a drug, Regulation (EC) No 1831/2003 and Regulation (EC) No 767/2009 may apply instead. The downstream process is high-shear dispersion of the extract in purified water at 1,500–3,000 rpm for 20–30 minutes, filtration through a 50 µm stainless steel or polypropylene bag filter to remove insoluble seed-coat fragments, addition of preservatives below 50°C to avoid thermal degradation, and hot filling at 85°C into 500 mL, 1 L, and 5 L HDPE containers with tamper-evident closures. Terminal product types are ready-to-use oral drenches for cattle, sheep, and goat operations where botanical supportive therapy is permitted under local veterinary regulations; the product is protected from light and stored below 30°C.